Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FBIO is in the long-term down -71% below S&P in 3 years.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||9.36 M||Cash From Investing Activities||-1.36 M||Cash From Operating Activities||-8.83 M||Gross Profit|
|Net Profit||-12.06 M||Operating Profit||-12.07 M||Total Assets||90.45 M||Total Current Assets||69.61 M|
|Total Current Liabilities||5.93 M||Total Debt||24.01 M||Total Liabilities||30.3 M||Total Revenue||500 K|
|High 52 week||3.83||Low 52 week||0.57||Last close||1.9||Last change||-1.55%|
|RSI||62.9||Average true range||0.19||Beta||1.26||Volume||144.58 K|
|Simple moving average 20 days||10.34%||Simple moving average 50 days||7.61%||Simple moving average 200 days||22.1%|
|Performance Week||6.74%||Performance Month||30.14%||Performance Quart||-12.84%||Performance Half||71.17%|
|Performance Year||-47.8%||Performance Year-to-date||120.93%||Volatility daily||6.73%||Volatility weekly||15.06%|
|Volatility monthly||30.86%||Volatility yearly||106.89%||Relative Volume||321.39%||Average Volume||784.81 K|
|New High||New Low|
2019-11-12 07:30:00 | Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
2019-11-10 09:16:08 | Do Insiders Own Shares In Fortress Biotech, Inc. NASDAQ:FBIO?
2019-09-26 08:30:00 | Fortress Biotech to Present at October 2019 Investor Conferences
2019-09-26 08:30:00 | Mustang Bio to Participate in October 2019 Investor Conferences
2019-09-09 08:00:00 | Mustang Bio to Present at Scientific Conferences in September 2019
2019-09-04 08:30:00 | Checkpoint Therapeutics to Present at September 2019 Investor Conferences
2019-08-29 08:00:00 | Mustang Bio to Present at September 2019 Investor Conferences
2019-08-27 11:42:12 | A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019
2019-08-26 11:49:02 | A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019
2019-08-22 08:00:00 | Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency XSCID granted regenerative medicine advanced therapy RMAT designation from FDA
2019-08-19 08:00:00 | Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors
2019-08-05 08:00:00 | FDA Clears IND for Mustang Bio’s MB-102 CD123 CAR T
2019-08-01 08:00:00 | Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
2019-07-12 10:13:21 | Have Insiders Been Selling Fortress Biotech, Inc. NASDAQ:FBIO Shares?
2019-07-01 08:30:00 | Checkpoint Therapeutics Added to Russell 2000® Index
2019-05-17 09:35:01 | Will Fortress Biotech to Surge Higher?
2019-05-13 08:00:00 | Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019
2019-05-10 07:44:32 | Fortress Biotech: 1Q Earnings Snapshot
2019-05-08 09:25:00 | Mustang Bio Announces Full Exercise of Option
2019-04-30 07:30:00 | Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors